This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Photosensitivity Disorders  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Atorvastatin calcium is a hypocholesterolemic drug belonging to the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor family and is widely used to treat hypercholesterolemia. To our knowledge, we report the first case of phototoxic effects induced by atorvastatin with an action spectrum and an in vitro absorption spectrum in the UV-B range.

Report of a Case

A 54-year-old woman presented with stage IV-A Sézary syndrome of 3 years' duration. Her therapy was failing. She had been treated for the past 5 years with atorvastatin calcium at the dosage of 40 mg/d and followed a low-fat diet, but her lipid levels did not return to reference range. Because the erythroderma persisted, treatment with bexarotene was suggested, and this involved increasing the dosage of atorvastatin calcium to 80 mg/d in March 2003 (when the sun was stronger). Seven days later, the patient presented with an edematous actinic erythema that affected her face, the V area of her chest, . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION
Marie-Claude Marguery, MD; Nadia Chouini-Lalanne, PhD; Charlotte Drugeon; Agnés Gadroy, MD; Paule Bayle, MD; Fabiènne Journe, MD; Jacques Bazex, MD; Michel D’Incan, MD, PhD

RELATED ARTICLE

Porphyria Cutanea Tarda Induced by the Use of Pravastatin
Andreas Schindl, Franz Trautinger, Heidemarie Pernerstorfer-Schön,, Christophoros Konnaris, and Herbert Hönigsmann
Arch Dermatol. 1998;134(10):1305-1306.
EXTRACT | FULL TEXT